Modern developments in the pre-clinical and clinical investigation into rheumatic and allergic diseases have primarily altered the exercise of rheumatology and allergy and advanced the prognosis of patients. The development of the TNF (Tumor Necrosis Factor) barrier as a novel and extremely effective cure for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease is one of the utmost exciting innovations in 21st-century medicine. This accomplishment was made possible by pre-clinical research that acknowledged TNF alpha as a vital player in the pathogenesis of inflammatory arthritis in both rodent models and human disease. These simple discoveries were made possible by major advances in the fields of immunology, molecular biology, and genetics.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
